- Home
- RVPHW vs VINP Comparison
RVPHW vs VINP Comparison
Compare RVPHW & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- VINP
- Stock Information
- Founded
- RVPHW N/A
- VINP 2009
- Country
- RVPHW United States
- VINP Brazil
- Employees
- RVPHW 15
- VINP N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- RVPHW Health Care
- VINP Finance
- Exchange
- RVPHW Nasdaq
- VINP Nasdaq
- Market Cap
- RVPHW N/A
- VINP N/A
- IPO Year
- RVPHW 2018
- VINP 2021
- Fundamental
- Price
- RVPHW $0.12
- VINP $10.24
- Analyst Decision
- RVPHW
- VINP Strong Buy
- Analyst Count
- RVPHW 0
- VINP 2
- Target Price
- RVPHW N/A
- VINP $14.50
- AVG Volume (30 Days)
- RVPHW N/A
- VINP 74.9K
- Earning Date
- RVPHW N/A
- VINP 11-06-2024
- Dividend Yield
- RVPHW N/A
- VINP 6.64%
- EPS Growth
- RVPHW N/A
- VINP N/A
- EPS
- RVPHW N/A
- VINP 0.54
- Revenue
- RVPHW N/A
- VINP $85,532,639.00
- Revenue This Year
- RVPHW N/A
- VINP $8.38
- Revenue Next Year
- RVPHW N/A
- VINP $11.26
- P/E Ratio
- RVPHW N/A
- VINP $19.05
- Revenue Growth
- RVPHW N/A
- VINP 9.37
- 52 Week Low
- RVPHW N/A
- VINP $9.01
- 52 Week High
- RVPHW N/A
- VINP $11.85
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- VINP 55.61
- Support Level
- RVPHW N/A
- VINP $9.88
- Resistance Level
- RVPHW N/A
- VINP $10.28
- Average True Range (ATR)
- RVPHW 0.00
- VINP 0.19
- MACD
- RVPHW 0.00
- VINP 0.07
- Stochastic Oscillator
- RVPHW 0.00
- VINP 94.81
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.